Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Long-term evaluation of alendronate treatment on the healing of calvaria bone defects in rats. Biochemical, histological and immunohistochemical analyses

Full text
Author(s):
de Molon, Rafael Scaf [1] ; Fiori, Leslie Cristine [1] ; Arruda Verzola, Mario Henrique [1] ; Belluci, Marina Montosa [1] ; de Souza Faloni, Ana Paula [2] ; Rodrigues Pereira, Rosa Maria [3] ; Tetradis, Sotirios [4, 5] ; Perez Orrico, Silvana Regina [1, 6]
Total Authors: 8
Affiliation:
[1] Sao Paulo State Univ UNESP, Sch Dent, Dept Diag & Surg, Araraquara, SP - Brazil
[2] Univ Ctr Araraquara UNIARA, Dept Hlth Sci, Implantol Post Grad Course, Sao Paulo - Brazil
[3] Univ Sao Paulo, Sch Med, Dept Rheumatol, BR-05508900 Sao Paulo - Brazil
[4] Univ Calif Los Angeles, Mol Biol Inst, Los Angeles, CA 10833 - USA
[5] Univ Calif Los Angeles, Sch Dent, Div Diagnost & Surg Sci, Los Angeles, CA 10833 - USA
[6] Union Coll Great Lakes UNILAGO, Adv Res Ctr Med, Sao Jose Do Rio Preto, SP - Brazil
Total Affiliations: 6
Document type: Journal article
Source: ARCHIVES OF ORAL BIOLOGY; v. 117, SEP 2020.
Web of Science Citations: 0
Abstract

Objective: The aim of this study was to investigate the effects of the long-term alendronate administration on bone healing in defects created in rat calvarias. Materials and methods: Female Wistar rats were randomly distributed into 2 groups: Control (CTL): animals received saline solution once a week; and Alendronate (ALD): rats underwent alendronate treatment (1 mg/kg/weekly). After 120 days from the commencement of treatment, a critical size defect was created in all animals, and 10 animals from each group were sacrificed at 5, 10, 15, 20, 25, 30, 45 and 60-days after the defect creation. On the day of sacrifice, urine and blood samples were collected for determination of the serum levels of bone resorption and formation markers by enzyme linked immunosorbent assay, and the urinary concentration of deoxypyridinoline. Bone mineral density (BMD) in the femurs, descriptive histology, tartrate-resistant acid-phosphatase staining and immunohistochemical analyzes were assessed in the calvaria. Results: Alendronate group showed increased BMD compared to the test group. The concentration of C-terminal telopeptide of type I collagen and deoxypyridinoline decreased significantly, and the concentration of amino-terminal propeptide of procollagen type 1 and osteocalcin were significant lower in the alendronate group. Immunohistochemical analysis showed significant downregulation in the inducible nitric oxide synthase, runtrelated transcription factor-2, cathepsin-K and receptor activator of nuclear factor kappa-B ligand expression in the alendronate group. Vascular endothelial growth factor and osteopontin were upregulated in the later periods of alendronate group. Conclusions: Our results suggest that long-term treatment with alendronate did not compromise the repair processing of critical size defects in rat. (AU)

FAPESP's process: 15/21697-5 - A potentially new class of bone-protective drugs, phytocystatin from sweet orange Csin-CPI-2, as possible therapeutic candidate for treatment of bone diseases.
Grantee:Rafael Scaf de Molon
Support Opportunities: Scholarships in Brazil - Post-Doctoral